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Abstract
Background: Articular manifestations are common in systemic lupus erythematosus (SLE) whereas erosive disease
is not. Antibodies to cyclic citrullinated peptide (anti-CCP) are citrulline-dependent in rheumatoid arthritis (RA),
whereas the opposite is suggested in SLE, as reactivity with cyclic arginine peptide (CAP) is typically present.
Antibodies targeting carbamylated proteins (anti-CarP) may occur in anti-CCP/rheumatoid factor (RF)-negative cases
long before clinical onset of RA. We analysed these antibody specificities in sera from European patients with SLE in
relation to phenotypes, smoking habits and imaging data.
Methods: Cases of SLE (n = 441) from Linköping, Sweden, and Leiden, the Netherlands, were classified according to
American College of Rheumatology (ACR) and/or Systemic Lupus Erythematosus International Collaborating Clinics
(SLICC) criteria. IgG anti-CCP, anti-CAP and anti-CarP were analysed by immunoassays. Radiographic data from 102
Swedish patients were available.
Results: There were 16 Linköping (6.8%) and 11 Leiden patients (5.4%) who were anti-CCP-positive, of whom
approximately one third were citrulline-dependent: 40/441 (9.1%) were anti-CarP-positive, and 33% of the
anti-CarP-positive patients were identified as anti-CCP-positive. No associations were found comparing anti-CCP or
anti-CarP with ACR-defined phenotypes, immunologic abnormalities or smoking habits. Radiographically confirmed
erosions were found in 10 patients, and were significantly associated with anti-CCP, anti-CarP and RF.
Musculoskeletal ultrasonography scores were higher in anti-CCP-positive compared to anti-CCP-negative patients.
Conclusions: In the hitherto largest anti-CarP study in SLE, we demonstrate that anti-CarP is more prevalent than
anti-CCP and that the overlap is limited. We obtained some evidence that both autoantibodies seem to be
associated with erosivity. Similar pathogenetic mechanisms to those seen in RA may be relevant in a subgroup of
SLE cases with a phenotype dominated by arthritis.
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Background
In clinical practice, the diagnosis of systemic lupus
erythematosus (SLE) is often based on the involvement
of at least two organ systems combined with a diversity
of immunological abnormalities [1]. The presence of
antinuclear antibodies (ANA) and reduced levels of cir-
culating complement proteins are typical immunological
abnormalities in SLE, and both of these are included in
the most recent proposal of classification criteria [2].
Over the years, several attempts to link specific autoanti-
bodies to certain clinical phenotypes of SLE have been
made. For instance, antibodies against double-stranded
DNA (dsDNA) and C1q are commonly found in lupus
nephritis [3, 4], anti-Ro/SSA antibodies often coincide
with lupus-related rash and photosensitivity [5], and
anti-phospholipid antibodies are frequently found in
patients with SLE who have thromboembolic events [6].
Detection of antibodies against cyclic citrullinated pep-
tide (anti-CCP) is an important diagnostic and prognos-
tic tool in arthritis, as it is highly specific for rheumatoid
arthritis (RA) and predictive of erosive disease. While a
positive anti-CCP test in RA is typically citrulline-
dependent [7], it has been suggested that anti-CCP in
other conditions is generally not, and thus, also reacts
with the corresponding cyclic arginine peptide (anti-
CAP) [8, 9]. During the last years, it has been repeatedly
shown that antibodies targeting carbamylated proteins
(anti-CarP) may occur in anti-CCP/rheumatoid factor
(RF) negative cases [10–12]. Like RF and anti-CCP, anti-
CarP antibodies can also be detected many years before
the onset of RA [13–15].
The process of carbamylation is mediated by a chem-
ical reaction of cyanate with mainly lysine residues in
proteins [16]. Cyanate is present in the body in equilib-
rium with urea. Inflammation, smoking and renal failure
have been reported to increase the non-enzymatic post-
translational modification in which cyanate binds to
molecules containing primary amine or thiol groups and
forms carbamyl groups [16]. Carbamylation of proteins
can lead to the loss of tolerance with formation of
antibodies directed against carbamylated proteins (anti-
CarP antibodies) in susceptible individuals [10–12].
Over the last years, this novel group of autoantibodies
has been intensively studied in patients before the onset
of clinical RA symptoms and in patients with established
RA, in relation to prognostic factors such as anti-CCP/
RF and to disease outcomes (i.e. radiological progres-
sion) [10, 17, 18]. Anti-CarP has also been recently
reported in primary Sjögren’s syndrome, and found to be
strongly associated with increased focal lymphocyte infil-
tration, formation of ectopic germinal centre-like struc-
tures, and to the degree of affected salivary gland
function [19]. To our knowledge, only two previous
small studies have addressed the occurrence of anti-
CarP antibodies in SLE. Thus, Scinocca et al. reported
the occurrence of anti-CarP (homocitrullinated fibrino-
gen) antibodies in 49% of 81 patients with RA, but in
none of 37 patients with SLE, 37 patients with psoriatic
arthritis, or 27 healthy controls [20]. In the study by
López-Hoyos et al., 48% (16/33) of anti-CCP/RF-nega-
tive patients with elderly-onset RA were judged
seropositive for anti-CarP compared to 39% (48/124) of
patients with polymyalgia rheumatica, and 11% (4/37) of
patients with SLE [21].
Although articular involvement is common in SLE (at
least 80%) and often constitutes the presenting
symptom, it has historically received limited attention
[22, 23]. A plausible reason hereto is that arthritis causes
significant problems to the patient at disease onset, but
often responds rather well to treatment with glucocorti-
coids, hydroxychloroquine and methotrexate [22].
Development of deformities is occasionally seen, but the
vast majority of patients with SLE do not develop radio-
graphically evident erosions [22]. Accordingly, several
investigators have estimated the frequency of erosive
arthritis in SLE to be 2–5%, but the finding of erosions
on radiography often complicates the distinction
between SLE and RA [22, 24]. As a result, the concept
of “rhupus” was introduced to describe patients who
simultaneously fulfil classification criteria for both con-
ditions [25, 26]. It is still a matter of debate as to
whether this group represents a true overlap of RA and
SLE, rather than a subset of SLE [27, 28].
Hitherto, only a few studies of lupus arthritis based on
imaging modalities other than conventional radiography
have been published. A limited number of studies have
evaluated magnetic resonance imaging (MRI) in the as-
sessment of patients with articular involvement in SLE
[29–32]. Recently, Ball and colleagues demonstrated that
MRI is highly sensitive in identifying erosions, synovitis
and bone oedema, independently of anti-CCP and RF
antibody status [32]. In SLE, there are some reports
based on musculoskeletal ultrasonography (US), but so
far this modality has seldom been used in clinical
routine practice [31, 33].
The primary aim of this study was to describe the
presence of citrulline-dependent anti-CCP and anti-CarP
antibodies in 441 well-characterized patients within two
European SLE cohorts. Second, in the Swedish dataset,
we aimed to investigate the associations between auto-
antibody status and articular involvement as defined by
classification criteria, conventional radiographic data and
evaluation with musculoskeletal US.
Methods
Discovery cohort
Patients diagnosed with SLE (n = 236) were included in
the discovery cohort. All patients took part in the
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prospective, structured follow-up programme “KLUR-
ING” (the Swedish acronym for Clinical Lupus Register
In Northeastern Gothia) at the rheumatology outpatient
clinic, University Hospital, Linköping, Sweden. The
patient material has previously been described in detail
[3, 34]. Patients were recruited consecutively and classi-
fied as having SLE according to the 1982 American
College of Rheumatology (ACR) criteria and/or the 2012
Systemic Lupus International Collaborating Clinics clas-
sification criteria (SLICC)-12 [2, 35]. Most patients
represented prevalent cases (83%), but 41 patients (17%)
had newly diagnosed disease at inclusion. Information
on smoking habits (current/former/never) and activity
limitations defined according to the validated Swedish
version of the health assessment questionnaire (HAQ)
was recorded at the time of blood sampling [36]. Further
patient characteristics are summarized in Table 1.
It should be emphasized that the definition of arthritis
slightly differs between the ACR-82 and SLICC-12 cri-
teria. Whereas ACR-82 requires “non-erosive arthritis
involving ≥2 peripheral joints, characterized by tender-
ness, swelling, or effusion”, the presence of “synovitis
involving 2 or more joints, characterized by swelling or
effusion OR tenderness in 2 or more joints and at least
30 minutes of morning stiffness” is demanded to meet
the SLICC-12 arthritis criterion.
Replication cohort
A total of 205 consecutive patients with SLE were
included in the replication cohort. All patients were
selected from the Leiden NPSLE clinic, at the rheuma-
tology department, Leiden University Medical Center
(LUMC), the Netherlands. The LUMC serves as a
national referral centre for patients with SLE suspected
of having neuropsychiatric involvement. All patients
included were admitted for one day and underwent a
complete examination that has previously been
described in detail [37]. All patients were classified as
having SLE according to the 1997 updated ACR-82 and/
or the SLICC-12 criteria [2, 38]. Data on gender, smok-
ing status and ethnicity were retrospectively recorded.
Detailed patient characteristics relevant to the present
study are summarized in Table 1.
The following definitions of smoking habits were used
in both cohorts [39]. “Former smoker” means to have
ever been a regular smoker; occasional smokers were
not included. “Ever smoker” constitutes the sum of
“former smoker” and “current smoker”.
Laboratory analyses
In the discovery cohort, IgG-class anti-CCP and anti-
CAP antibodies were analysed by enzyme-linked im-
munosorbent assays (CCPlus and anti-CAP respectively,
Euro-Diagnostica, Malmö, Sweden). Levels ≥25 units/
mL defined a positive test as suggested by the manufac-
turer. Citrulline dependency was defined as a higher
antibody level obtained in the anti-CCP test than in the
anti-CAP test. RF was detected by nephelometry at the
clinical immunology department, University Hospital,
Linköping, Sweden.
For the replication cohort, anti-CCP and anti-CAP
antibodies were analysed using an in-house CCP2 assay
with a defined cutoff ≥25 units/mL [40]. Healthy con-
trols (n = 193) who were living in the Leiden area, were
included for comparison. Briefly, biotinylated CCP2
citrulline and corresponding arginine control peptide
were coupled to streptavidin-coated enzyme-linked im-
munosorbent assay (ELISA) plates. Serum samples were
diluted 1:50 and bound IgG was detected using rabbit
anti-human IgG horseradish peroxidase (HRP) (DAKO,
Glostrup, Denmark).
Analysis of IgG anti-CarP antibody in both cohorts
was performed in Leiden, using a previously described
immunoassay detecting antibodies against carbamylated
fetal calf serum proteins [10]. Other laboratory analyses,
including IgM RF quantified by fluoroenzyme immuno-
assay, were performed at the routine diagnostic labora-
tory of the Leiden University Medical Center, Leiden,
the Netherlands.
Radiology
Through meticulous chart review of each patient, we
identified all conventional radiographs of the hands,
wrists and/or feet, obtained at the University Hospital,
Linköping (discovery cohort). The results were scruti-
nized by an experienced rheumatologist (MZ) who was
blinded to the patients’ antibody status. In cases where
erosions had been identified by the radiologist and in all
cases with indistinct findings, the radiographs were
finally evaluated by MZ to determine whether erosions
were present.
Musculoskeletal US
In the discovery cohort, all anti-CCP-positive cases plus
just as many anti-CCP-negative cases, matched accord-
ing to sex, age, disease duration and present prednisol-
one dose, were systematically investigated with
musculoskeletal US by an experienced examiner (MZ)
blinded to the patients’ antibody profiles and conven-
tional radiography results. Characteristics of the 32
patients, representing a subgroup of the discovery
cohort, are shown in Table 2.
US examination was performed using the LOGIQ-E9
(GE Healthcare, Milwaukee, WI, USA) with a linear scan-
ner 6–15 MHz. All patients were examined with the same
settings for both B-mode (grey scale) and power Doppler
(PD). The protocol included dorsal assessments of the
following 36 joints: bilateral radiocarpal, intercarpal, distal
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Table 1 Clinical and immunological features of the 441 included patients








Female, % (n) 88% (207) 89% (183) N.S.
Age, years, median (range) 54 (19–94) 42 (13–80) <0.001
Disease duration, years, median (range) 15 (0–52) 8 (0–32) <0.001
Caucasian ethnicity, % (n) 93% (219) 69% (142) <0.001
Conventional radiology available, % (n) 43% (102) N.A.
Erosions on x-ray, % (n) 4.2% (10)a N.A.
HAQ score (median, range) 0.13 (0-3) N.A.
Ever smoker (former or current), % (n) 45% (107) 43% (88) N.S.
Meeting ACR-82, % (n) 85% (201) 91% (188) 0.038
Meeting SLICC-12, % (n) 99% (233) 99% (203) N.S.
Clinical phenotypes (SLICC-12 definitions on criteria 1 − 11), % (n)
1) Acute cutaneous lupus 45% (106) 53% (108) N.S.
2) Chronic cutaneous lupus 15% (36) 18% (36) N.S.
3) Oral ulcers 12% (29) 32% (66) <0.001
4) Non-scarring alopecia 22% (51) 19% (39) N.S.
5) Synovitis 76% (180) 70% (143) N.S.
6) Serositis 37% (87) 23% (48) 0.003
Pleuritis 35% (83) 18% (37) <0.001
Pericarditis 14% (34) 14% (28) N.S.
7) Renal 28% (66) 26% (53) N.S.
8) Neurologic 11% (26) 22% (44) 0.004
Seizures 4.2% (10) 5.4% (11) N.S.
Psychosis 1.7% (4) 4.4% (9) N.S.
Mononeuritis multiplex 0.4% (1) 0% (0) N.S.
Myelitis 0.4% (1) 2.9% (6) N.S.
Peripheral or cranial neuropathy 5.1% (12) 8.3% (17) N.S.
Acute confusional state 0.8% (2) 2% (4) N.S.
9) Haemolytic anaemia 4.7% (11) 5.9% (12) N.S.
10) Leukopenia and/or lymphopenia 52% (122) 30% (62) <0.001
11) Thrombocytopenia 12% (28) 18% (37) N.S.
Raynaud 26% (61) 40% (82) 0.002
Interstitial lung disease 3.5% (8) 3.4% (7) N.S.
Immunological features (SLICC-12 definitions on criteria 1 to 6), % (n)
1) Antinuclear antibody (ANA) 100% (236) 100% (205) N.S.
2) Anti-dsDNA antibody (anti-dsDNA) 50% (118) 56% (115) N.S.
3) Anti-Smith antibody (anti-Sm) 8.1% (19) 10% (21) N.S.
4) Antiphospholipid antibody 59% (139) 44% (90) 0.002
Lupus anticoagulant 35% (69)b 32% (65) N.S.
Anti-cardiolipin antibody 34% (80) 24% (49) 0.027
Anti-β2-glycoprotein I antibody 26% (62) 18% (27)c N.S.
5) Low complement 53% (124) 50% (102) N.S.
6) Direct Coombs test 56% (59)d 23% (38)e <0.001
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radioulnar, metacarpophalangeal (MCP) I–V, interphalan-
geal (IP) thumb joints, proximal interphalangeal (PIP II-V),
and metatarsophalangeal (MTP) joint I-V. In addition, six
tendons (extensor carpi ulnaris in the wrist, tibialis poster-
ior and flexor digitorum longus in the feet) were evaluated.
To grade synovitis, we used the scoring system of
Szkudlarek et al. in which synovial hypertrophy is graded
0–3 (0 = no thickening, 3 = synovial thickening bulging over
the tops of the periarticular bones and extension over the
diaphysis of at least one side) and perfusion 0–3 (0 = no
Doppler signals in the synovium, 3 = confluent Doppler
signals in more than one half of the synovium) [41, 42].
Statistics
Potential associations between antibody status and clin-
ical characteristics were tested by Fisher’s exact test for
categorical variables and by the Mann-Whitney U test
for numerical variables. The Mann-Whitney U test or
chi-square test was used to evaluate differences between
the cohorts. Statistical analyses were performed using
SPSS v23.
For analyses where we had prior hypotheses, a signifi-
cance level of 5% was regarded as statistically significant
(two-sided p values <0.05). For all other tests performed
in a more exploratory manner, the exact p values (if p
was <0.05) are reported as the reference.
Results
Comparison between cohorts
As shown in Table 1, the size of the two cohorts was
similar, whereas in some instances there were significant
differences in the clinical phenotypes according to the
classification criteria that were fulfilled (oral ulcers, sero-
sitis, neurological involvement, Raynaud). Significantly
more patients in the discovery cohort were older, had
longer disease duration, and were Caucasian than in the
replication cohort. In addition, laboratory criteria such
as the presence of leukopenia/lymphocytopenia, anti-
phospholipid antibody, anti-snRNP antibody, anti-La/
SSB antibody, RF and the direct Coombs test differed
between the cohorts.






Age, years, median 58 58 N.S.
Disease duration, years, median 10.5 10.5 N.S.
Female, number 14 13 N.S.
Fulfilled ACR-82 criteria number, median 4 4 N.S.
Meeting arthritis criterion according to ACR-82, number 13 14 N.S.
Meeting nephritis criterion according to ACR-82, number 4 2 N.S.
Conventional radiographs available (hands/wrists/feet) 16 16 N.S.
Erosions on radiography, number of individuals 4 0 N.S.
HAQ score, median 0.5 0.19 N.S.
Ever smoker, number of individuals 9 3 N.S.
Rheumatoid factor positive, number of individuals 6 1 N.S.
anti-CarP antibody level, median 275 102 0.04
anti-CarP positive, number of individuals 6 1 N.S.
Daily dosage of prednisolone, median 2.5 2.5 N.S.
ACR American College of Rheumatology, HAQ health assessment questionnaire, anti-CarP antibodies targeting carbamylated proteins, N.S. not significant
Table 1 Clinical and immunological features of the 441 included patients (Continued)
Anti-small nuclear ribonucleoprotein antibody (anti-snRNP) 37% (88) 17% (35) <0.001
Anti-Ro/Sjögren’s syndrome A antibody (SSA) 37% (88) 42% (87) N.S.
Anti-La/Sjögren’s syndrome B antibody (SSB) 28% (66) 13% (27) <0.001
Anti-cyclic citrulline peptide antibody (anti-CCP)f 6.8% (16) 5.4% (11) N.S.
Anti-carbamylated protein antibody (anti-CarP) 9.8% (23) 8.3% (17) N.S.
Rheumatoid factorf 25% (26)d 15% (31) 0.046
aCalculated in 236 patients. bData available on 195 patients. cData available on 148 patients. dData available on 107 patients. eData available on 164 patients. fNot
performed with identical assays. HAQ health assessment questionnaire, ACR American College of Rheumatology, SLICC Systemic Lupus Erythematosus International
Collaborating Clinics, ANA antinuclear antibodies, dsDNA double-stranded DNA, N.A. not applicable, N.S. not significant
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Presence of anti-CCP/CAP/CarP antibodies in SLE
In the discovery cohort, 16 patients (6.8%) were anti-
CCP-positive, 9 (56%) of whom were also anti-CAP-
positive using Euro-Diagnostica kits; however, only one
of the 9 anti-CCP/anti-CAP-positive patients had a
higher antibody level for anti-CAP than for anti-CCP in
the assays: 4 of the 7 patients with a positive citrulline-
dependent anti-CCP test had a history of biopsy-proven
lupus nephritis. There were 23 anti-CarP-positive
patients (9.8%); only 6 (26%) of the anti-CarP-positive
patients were identified as anti-CCP-positive (Fig. 1a).
In the replication cohort, 11 patients (5.4%) were anti-
CCP-positive, of whom 8 (73%) were also positive for
anti-CAP using in-house assays; in 4 of the 8 anti-CCP/
anti-CAP-positive patients, there was a higher optical
density signal for anti-CAP than for anti-CCP. There
were 17 anti-CarP-positive patients (8.3%), of whom 2
(12%) were also identified as anti-CCP-positive (Fig. 1b).
A limited number of samples from the discovery cohort
were also analysed with the anti-CCP in-house assay in
Leiden. The agreement between the assays was fair (rho
= 0.75; concordance 90%).
Associations between anti-CCP, anti-CarP, or RF and clin-
ical or other laboratory features
In the discovery cohort, neither anti-CCP nor anti-CarP
were associated with arthritis by classification according
to physical examination. However, the presence of anti-
Fig. 1 a-b Distribution of anti-carbamylated protein (anti-CarP)-positive, anti-cyclic citrullinated peptide (anti-CCP)-positive and anti-cyclic arginine
peptide (anti-CAP)-positive patients in the discovery cohort (n = 236) (a), and in the replication cohort (n = 205) (b)
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CarP was associated with neurological involvement as
defined by SLICC-12 (p = 0.028); this association was
particularly driven by the presence of cranial/peripheral
neuropathy (p = 0.021). On the contrary, anti-CarP was
less common among patients with a positive lupus
anticoagulant test (p = 0.012). Positive anti-CCP tests
were inversely related to anti-La/SSB (p = 0.007).
Smoking habits and HAQ score were not associated
with anti-CCP, anti-CarP or RF.
In the replication cohort, the presence of anti-CarP
was not significantly associated with neurological
involvement as defined by SLICC-12 (p = 0.126); and
there was no association with specific neurological mani-
festations included in the SLICC-12 criteria. Anti-CarP
was not associated with any other SLICC-12 definition
or SLE autoantibody. On the contrary, anti-CCP was more
common among patients with positive anti-Sm (p = 0.017).
There was no association between anti-CCP positivity and
anti-La/SSB. Smoking habits were not associated with anti-
CCP, anti-CarP or RF.
Associations between anti-CCP, anti-CarP or RF, and
radiography
In the Swedish cohort, conventional radiographs of the
hands, wrists and/or feet were available in 102 patients
(43%), and erosions (mostly demonstrated in the inter-
carpal, MCP and MTP joints) were identified in 10
patients. This corresponds to 4.2% calculated for the
entire Swedish cohort, and to 9.8% calculated strictly
for patients with radiographs available. Radiological
erosions were significantly associated with a positive
anti-CCP (p < 0.05), anti-CarP (p < 0.05) or RF (p < 0.05)
test, respectively.
All patients with a positive anti-CCP test underwent
radiography of the hands, wrists and feet. Thus, patients
with radiographs available were more often anti-CCP-
positive (16/102; 16%) as compared to patients without
radiographs (0/134; p < 0.001). Similarly, “ever”’ smokers
were significantly overrepresented among patients with
radiographs (55/102; 54%) compared to those without
(52/134; 39%; p = 0.025). There were no significant
differences in age, sex or fulfilment of the SLICC-12
arthritis criterion. Neither did the occurrence of anti-
CarP, anti-CAP or RF significantly differ according to
the availability of radiographic data.
Associations between anti-CCP, anti-CarP or RF, and mus-
culoskeletal US
In anti-CCP-positive patients, US examination of the
joints and tendons resulted in significantly higher arth-
ritis scores, but not tenosynovitis scores (Fig. 2a). There
were similar trends for anti-CarP and RF, but these
were not statistically significant (Fig. 2b–c). Patients
with radiological erosions had significantly higher arth-
ritis scores, but not tenosynovitis scores (Fig. 2d).
Individuals with ongoing prednisolone medication had
higher arthritis, but not tenosynovitis scores (Fig. 2e),
whereas fulfilment of the ACR criterion for arthritis did
not separate the groups (Fig. 2f ).
Fig. 2 a-f Standardized musculoskeletal ultrasonography grading of arthritis and tenosynovitis with grey scale (B-mode) and power Doppler (PD)
in 32 patients divided according to the presence of anti-cyclic citrullinated peptide (anti-CCP) (a), anti-carbamylated protein antibody (anti-CarP)
(b), rheumatoid factor (c), radiographically confirmed erosions (d), daily intake of prednisolone (e), and with regard to the fulfilment of the 1982
American College of Rheumatology (ACR) classification criterion 5 (arthritis) (f) [35]. Median and interquartile range are illustrated. * p < 0.05
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Associations between anti-CCP or anti-CarP, and the fulfil-
ment of RA classification
Besides meeting the classification criteria for SLE, we
evaluated to what extent patients with a positive anti-
CCP and/or anti-CarP antibody test simultaneously
fulfilled the 2010 ACR/European League Against
Rheumatism (EULAR) criteria for RA [43]. As illustrated
(Fig. 3), the likelihood of meeting the RA criteria was
higher with a positive anti-CCP compared to a positive
anti-CarP antibody test. However, when taking citrulline
dependency into account for the anti-CCP test this
difference was less pronounced, particularly in the
discovery cohort.
Discussion
This is hitherto the largest evaluation of anti-CarP anti-
bodies in SLE, and the first study on anti-CarP in a
European SLE population. Herein, we demonstrated
similar frequencies of anti-CarP-positive SLE patients in
the two cohorts (9.8% vs. 8.3%) and that the overlap with
anti-CCP antibodies is limited. Our findings are in line
with what has been reported by López-Hoyos et al., but
clearly higher than observed by Scinocca and co-workers
[20, 21]. The latter may be explained by a difference in
the antigen used for the detection of anti-CarP anti-
bodies (fibrinogen vs. fetal calf serum). Furthermore, we
found significant associations between all three RA-asso-
ciated antibodies (anti-CCP, anti-CarP and RF) and
radiographically confirmed erosions in the Swedish
dataset. Based on the results, we hypothesize that patho-
genetic mechanisms could be similar in RA and in a
small group of patients with SLE with a clinical pheno-
type dominated by arthritis [44]. Interestingly though,
60% of the patients with radiology proven erosions were
not identified by any of the antibodies.
Articular manifestations affect a majority of patients
with SLE, at least at some time during the disease course
(73% in the present study). However, only a minority of
the patients with SLE who have an arthritic phenotype
simultaneously meet RA classification criteria [24, 25,
31]. The presence of anti-CCP antibodies is considered
highly specific for RA, but can also be found in other
conditions, including SLE, where frequencies from 2–
17% have been described [9, 32, 45–51]. Whether or not
there is a true association between a positive anti-CCP
test and erosive arthritis in SLE remains an open ques-
tion, as several investigators have reported this [9, 46–
50], whereas others have not [31, 45]. Kakumanu et al.
reported a prevalence of 17% for anti-CCP positivity
among 329 patients with SLE but that citrulline-
dependent anti-CCP was mainly found in patients with
erosive arthritis, which involved only 26 patients [9].
Pooled data from the present study indicate that 10 of
27 anti-CCP-positive patients (37%) had citrulline-
dependent anti-CCP, which corresponds to 2.3% in the
whole study population.
As previously mentioned, smoking affects the carba-
mylation process [16] and smoking is also strongly
Fig. 3 Percentage of patients who, besides being classified as having systemic lupus erythematosus (SLE), also fulfilled the 2010 American College
of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis (RA) [43] provided they were: (1) anti-cyclic
citrullinated peptide (anti-CCP) antibody-positive, (2) identified as citrulline-dependent anti-CCP antibody-positive (i.e. higher anti-CCP than cyclic
arginine peptide (anti-CAP) antibody level), and (3) anti-carbamylated protein (anti-CarP) antibody-positive
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associated with anti-CCP-positive RA, especially in
patients with the HLA-DRB1/shared epitope [52]. Thus,
we anticipated that smoking would also be overrepre-
sented among anti-CarP-positive and anti-CCP-positive
patients with SLE. To our surprise, we did not detect
such associations in this evaluation. In line with our
findings, however, recent studies from Stockholm did
not identify any correlation between smoking habits and
anti-CCP in SLE [51], and anti-CarP was not signifi-
cantly associated with smoking in patients with RA [11].
Of potential interest in relation to these results, the
frequency of “ever” smokers in the discovery and replica-
tion cohorts was similar (approximately 45%), but
was clearly lower than in two early RA cohorts (TIRA-2
and EIRA-1) from southern and central Sweden, where
the frequency reached approximately 60% [52].
Evaluations with musculoskeletal US were performed
in 32 patients with SLE (whereof 16 were anti-CCP posi-
tive) in the discovery cohort, showing significantly
higher arthritis scores among anti-CCP-positive cases
(Fig. 2a). Previous studies on musculoskeletal US in SLE
with relevant comparators are scarce and a considerable
strength in the present study is the matched control
group (Table 2). Some studies have reported a higher
number of affected tendons in SLE, compared to what
we found [31, 53–55]. Interestingly, the effects of corti-
costeroids on B-mode/PD arthritis scores seemed to be
limited (Fig. 2e).
We also investigated which RA-associated
autoantibody-positive patients with SLE who simultan-
eously met the classification criteria for RA. This group
could be referred to as “rhupus”, although there is no
agreed definition for this overlap condition [25–27].
Although anti-citrullinated protein antibodies (ACPA)
are indeed included in the 2010 ACR/EULAR criteria
for RA, we used this most recent RA classification [43].
We found the risk of meeting RA criteria was higher
given a positive anti-CCP test as compared to a positive
anti-CarP antibody test (52% vs. 20%); when taking
citrulline dependency into account for the anti-CCP test,
this difference appeared to decrease. We considered
using the 1987 ACR RA criteria (which does not include
ACPA), but we were unable to retrieve sufficient data to
determine fulfilment of this classification.
Apart from the statistically significant connection
between a positive anti-CarP test and erosive arthritis in
our study, the presence of anti-CarP was associated
significantly with neurological involvement only in the
discovery cohort, whereas a non-significant trend was
found in the replication cohort. This may be due to the
small number of patients with this clinical symptom.
However, it is tempting to speculate that carbamylation
may have an effect on neural tissue. Of relevance to this
is the fact that supplementation of sodium cyanate to
patients suffering from sickle cell anaemia disrupts the
equilibrium between urea and cyanate in body fluids,
resulting in increased carbamylation and severe poly-
neuropathy as side effects [56]. Furthermore, in animal
models, cognitive impairment and loss of memory
functions have been described as a result of increased
carbamylation [57].
Whether or not anti-CarP antibodies can also be
found in patients receiving sodium cyanate is unknown.
It should be emphasized that both irreversible
neuropathy and cognitive impairment are recorded as
SLE damage accrual in the neuropsychiatric domain of
the SLICC/ACR damage index [58]. Although renal
function also affects the carbamylation process, we did
not find any association between anti-CarP and renal in-
volvement. The reason hereto is most likely that renal
flares in well-controlled SLE are identified early and
treated aggressively, resulting in a very small number of
patients having end-stage renal disease [59]. In addition,
carbamylation alone may not be sufficient for a break of
tolerance against carbamylated proteins [60].
Although radiology data were at hand for all cases
with a positive anti-CCP test, this was the case only for
a minority of patients in the discovery cohort and not at
all in the replication cohort, which is a limitation of our
study. Furthermore, in the musculoskeletal US evalua-
tions, it is likely that a larger number of evaluated
patients with different autoantibody profiles would have
enabled statistically significant and meaningful differ-
ences in anti-CarP and RF to be identified. Finally, anti-
CCP, anti-CAP and RF were analysed with different
assays in the two cohorts. The agreement with anti-CCP
was fair, but we cannot exclude small methodological
differences that might have influenced the results to
some extent.
Conclusions
In summary, we demonstrated that anti-CarP is more
common than anti-CCP in well-characterised SLE in
two European cohorts, whereas the overlap of these anti-
body specificities is limited. In the Swedish dataset we
obtained some evidence that both autoantibodies are
associated with erosive joint disease.
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